Stocks and Investing
Stocks and Investing
Tue, December 18, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, December 17, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, December 14, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
David Risinger Downgraded (AMRX) to Hold and Decreased Target to $18 on, Dec 14th, 2018
David Risinger of Morgan Stanley, Downgraded "Amneal Pharmaceuticals, Inc." (AMRX) to Hold and Decreased Target from $24 to $18 on, Dec 14th, 2018.
David has made no other calls on AMRX in the last 4 months.
There are 2 other peers that have a rating on AMRX. Out of the 2 peers that are also analyzing AMRX, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Dewey Steadman of "Canaccord Genuity" Maintained at Hold with Increased Target to $21 on, Tuesday, August 14th, 2018
This is the rating of the analyst that currently disagrees with David
- David Buck of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $28 on, Wednesday, August 22nd, 2018